Cormorant Private Healthcare Fund II, LP's Net Worth
$597 Million
Who is Cormorant Private Healthcare Fund II, LP?
Cormorant Private Healthcare Fund II, LP has an estimated net worth of $597 Million. This is based on reported shares across multiple companies, which include Design Therapeutics, Inc., Atea Pharmaceuticals, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., BioAtla, Inc., Rain Therapeutics Inc., Akouos, Inc., Olema Pharmaceuticals, Inc., GreenLight Biosciences Holdings, PBC, and MoonLake Immunotherapeutics.
SEC CIK
Cormorant Private Healthcare Fund II, LP's CIK is 0001747677
Past Insider Trading and Trends
2021 was Cormorant Private Healthcare Fund II, LP's most active year for acquiring shares with 15 total transactions. Cormorant Private Healthcare Fund II, LP's most active month to acquire stocks was the month of May. 2020 was Cormorant Private Healthcare Fund II, LP's most active year for disposing of shares, totalling 8 transactions. Cormorant Private Healthcare Fund II, LP's most active month to dispose stocks was the month of October. 2021 saw Cormorant Private Healthcare Fund II, LP paying a total of $56,250,000.00 for 35,787,698 shares, this is the most they've acquired in one year. In 2023 Cormorant Private Healthcare Fund II, LP cashed out on 9,188,659 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Design Therapeutics, Inc. (DSGN) Snapshot price: $2.3
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 5.11M |
$20.00 |
—
| 5.11M |
Mar 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Atea Pharmaceuticals, Inc. (AVIR) Snapshot price: $4.15
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 6.41M |
—
|
—
| 6.41M |
Nov 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Erasca, Inc. (ERAS) Snapshot price: $1.7
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4/A
| +2.93% | 307.69K |
$6.50 | $1,999,998.00 | 10.81M |
Dec 13
| |||
Form 4
| +2.93% | 307.69K |
$6.50 | $1,999,998.00 | 10.81M |
Dec 13
| |||
Form 4
|
∞
| 10.51M |
$16.00 |
—
| 10.51M |
Jul 20
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Monte Rosa Therapeutics, Inc. (GLUE) Snapshot price: $4.68
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.2M |
$19.00 |
—
| 3.2M |
Jun 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aerovate Therapeutics, Inc. (AVTE) Snapshot price: $20.52
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.03M |
$14.00 |
—
| 2.03M |
Jul 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||